Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MasterAlgaeon Jun 30, 2021 12:59pm
143 Views
Post# 33473727

RE:Phase 3 Delay

RE:Phase 3 DelayThat Covid delay was expected, hence the long drift down since the $6.00 mark. Let's hope that the Delta variant fades away in USA, Europe and elsewhere - otherwise...

What the mkt wants to see is the vote of confidence in H2S, and that Antibe is not going to do Phase III alone. (MasterAlgae won't even go there). That vote of confidence comes from another partnership, North American or European.

After the partnership announcement then the NASDAQ is a formality and as the CEO has stated the paperwork is ready to go.

Forestview wrote: So, see below for what Dan said.  Though things are opening up after Covid, there is likely a massive backlog...also, Nasdaq uplist is expected to be tied to a Phase 3 start, so eventhough it wasn't mentioned in the news release it's still happening.  Last thing - a CEO update is coming in a couple of weeks...

We will experience a 6-8 week delay due to new Covid-related restrictions in Ontario imposed on Phase 1 clinics in May (we now have to do the study in 3 waves rather than 2). And the FDA itself is behind on it’s timings for meeting. Say another 4 weeks. Putting these together means that we think it’s unlikely we’d get our meeting before Christmas. Tiny stuff, but it’s a retail stock market. We are focused on the big prize: positive Phase III and at the same time, partnering (look at our China Nuance deal). Not sure what you mean by ‘momentum’ – we’re not a promotional agency.


<< Previous
Bullboard Posts
Next >>